Freeline to Present at Upcoming Investor Conferences


LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today that Theresa Heggie, Chief Executive Officer, will present a company overview at the following virtual investor conferences in March:

  • H.C. Wainwright Global Life Sciences Conference on March 9, 2021, available on-demand beginning at 7.00 a.m. ET
  • Barclays Global Healthcare Conference on March 10, 2021, at 7:30 a.m. ET

The Company presentations from both conferences will be available on the investor relations section of the Freeline website at Senior management will also participate in virtual one-on-one meetings with investors at these conferences.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. We use our proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. Freeline’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.


David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
+1 (646) 668 6947

Julia Wilson
JW Communications
+44 (0) 7818 430877